ZVRA insider buying and SEC filings, explained
Zevra Therapeutics, Inc. · CIK 1434647
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- KEMPHARM, INC; KEMPHARM INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$2.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 12, 2026 | Planned (10b5-1) | Neil F. McFarlane (CEO and Director) sold 20,000 shares at about $11.25 ($225K), marked as a 10b5-1 plan trade. Holdings down 5% to 417,225 shares. | SEC filing Filed Oct 13, 2026, 4:24 PM ET |
| Aug 14, 2026 | Planned (10b5-1) | Rahsaan Thompson (Chief Legal & Compliance) sold 42,666 shares at about $11.13 ($475K), marked as a 10b5-1 plan trade. Holdings down 53% to 37,569 shares. | SEC filing Filed Aug 17, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Rahsaan Thompson (Chief Legal & Compliance) sold 34,557 shares at about $12.68 ($438K), marked as a 10b5-1 plan trade. Holdings down 30% to 80,235 shares. | SEC filing Filed Jun 23, 2026 |
| May 11, 2026 | Planned (10b5-1) | Rahsaan Thompson (Chief Legal & Compliance) sold 1,794 shares at $11.30 ($20K), marked as a 10b5-1 plan trade. Holdings down 4% to 48,125 shares. | SEC filing Filed May 13, 2026 |
| Feb 9, 2026 | Planned (10b5-1) | Neil F. McFarlane (CEO and Director) sold 14,625 shares at about $8.56 ($125K), marked as a 10b5-1 plan trade. Holdings down 4% to 387,225 shares. | SEC filing Filed Feb 10, 2026 |
| Feb 3, 2026 | Planned (10b5-1) | Joshua Schafer (CCO) sold 10,500 shares at about $9.19 ($96K), marked as a 10b5-1 plan trade. Holdings down 14% to 62,278 shares. | SEC filing Filed Feb 4, 2026 |
| Feb 3, 2026 | Planned (10b5-1) | Timothy J. Sangiovanni (SVP, Finance & Corp Controller) sold 3,000 shares at about $9.18 ($28K), marked as a 10b5-1 plan trade. Holdings down 9% to 29,590 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 30, 2026 | Planned (10b5-1) | Timothy J. Sangiovanni (SVP, Finance & Corp Controller) sold 1,750 shares at about $8.82 ($15K), marked as a 10b5-1 plan trade. Holdings down 8% to 20,924 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Planned (10b5-1) | Joshua Schafer (CCO) sold 3,375 shares at about $8.83 ($30K), marked as a 10b5-1 plan trade. Holdings down 8% to 37,444 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Planned (10b5-1) | Adrian W Quartel (Chief Medical Officer) sold 4,533 shares at about $8.83 ($40K), marked as a 10b5-1 plan trade. Holdings down 32% to 9,723 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 30, 2026 | Planned (10b5-1) | Rahsaan Thompson (Chief Legal & Compliance and Secretary) sold 4,080 shares at about $8.83 ($36K), marked as a 10b5-1 plan trade. Holdings down 8% to 49,919 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Neil F. McFarlane (CEO and Director) sold 91,000 shares at about $9.38 ($854K), marked as a 10b5-1 plan trade. Holdings down 20% to 364,350 shares. | SEC filing Filed Feb 2, 2026 |
21 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:08 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ZVRA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.